In HIV, Greater BMD Decline for Immediate Versus Delayed ART

This article originally appeared here.
Share this content:
In HIV, Greater BMD Decline for Immediate Versus Delayed ART
In HIV, Greater BMD Decline for Immediate Versus Delayed ART

FRIDAY, June 30, 2017 (HealthDay News) -- Immediate antiretroviral (ART) initiation at HIV diagnosis is associated with greater bone mineral density (BMD) declines compared with deferred initiation, according to a study published online June 26 in the Journal of Bone and Mineral Research.

Jennifer F. Hoy, M.B.B.S., from Monash University and the Alfred Hospital in Melbourne, Australia, and colleagues compared the effect of early ART (CD4 <500 cells/µL) with deferred ART on the change in BMD, measured annually at the lumbar spine and hip using dual energy X-ray absorptiometry (DXA). Baseline and follow-up DXA scans were available for 195 participants in the immediate group and 204 in the deferred group.

The researchers found that, compared with deferred ART, immediate ART correlated with significantly greater BMD declines at the hip (−2.5 versus −1.0 percent; difference, −1.5 percent) and spine (−1.9 versus −0.4 percent; difference, −1.6 percent), through 2.2 years mean follow-up. The greatest declines in BMD were seen in the first year of ART. Spine BMD stabilized in the immediate ART group after one year, while hip BMD declined progressively over two years. BMD changes were similar in the immediate and deferred groups after year one.

"All HIV treatment guidelines now recommend ART initiation at HIV diagnosis because of the reduced risk of serious clinical outcomes," the authors write. "Better understanding of the longer-term consequences of the observed reductions in BMD is needed."

Several pharmaceutical companies donated antiretroviral drugs.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

For patients with relapsed or refractory B-cell ALL who have received one or two prior treatments

Online Nursing Education Can Up Patient Use of VTE Prophylaxis

Online Nursing Education Can Up Patient Use of ...

Online training aims to make sure those hospitalized get treatment to prevent venous thromboembolism

On-Pump CABG Leads to Higher Rates of Five-Year Survival

On-Pump CABG Leads to Higher Rates of Five-Year ...

Study compared coronary-artery bypass grafting surgery, with/without cardiopulmonary bypass

is free, fast, and customized just for you!

Already a member?

Sign In Now »